Primary prophylaxis of <i>Pneumocystis jirovecii</i> pneumonia (PCP) in people with HIV (PWH) and CD4+ counts <200 cells/μL using trimethoprim/sulfamethoxazole (TMP-SMX) is highly effective but often poorly tolerated. The gene discussed is CD4; the disease is pneumocystosis.